Lien studied pharmaceutical sciences where she focused on targeted cancer therapy in her master thesis. After her studies, she did an IWT-funded PhD in the lab of Biopharmaceutical Technology of Prof. Bruno De Geest at Ghent University where she focused on the design of immune-modulating generic polymeric strategies for personalized cell-based cancer vaccination.
During her PhD she went abroad as FWO-funded visiting researcher in the lab of Prof. Aaron Esser-Kahn at the University of California, Irvine where she researched TLR-ligand adjuvant functionalization of cancer vaccines. She published seven first-author A1 publications and is co-author on multiple different scientific papers.
Lien has profound expertise in the immune-oncology field and in-depth knowledge of tumor immuno-biology and therapeutic strategies, As CDO at myNEO Therapeutics, Lien leads the camyotope drug development department.
Lien studied pharmaceutical sciences where she focused on targeted cancer therapy in her master thesis. After her studies, she did an IWT-funded PhD in the lab of Biopharmaceutical Technology of Prof. Bruno De Geest at Ghent University where she focused on the design of immune-modulating generic polymeric strategies for personalized cell-based cancer vaccination.
During her PhD she went abroad as FWO-funded visiting researcher in the lab of Prof. Aaron Esser-Kahn at the University of California, Irvine where she researched TLR-ligand adjuvant functionalization of cancer vaccines. She published seven first-author A1 publications and is co-author on multiple different scientific papers.
Lien has profound expertise in the immune-oncology field and in-depth knowledge of tumor immuno-biology and therapeutic strategies, As CDO at myNEO Therapeutics, Lien leads the camyotope drug development department.